Lasa Supergenerics Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2017 • Domestic Sales: 100.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Working capital cycle has improved - days down from -10 to -38
- Company generates healthy free cash flow
- Company maintains a comfortable, low leverage position
CONS
- Company is loss-making at the operating / net level
- Company has a low return on equity of -17.2% over last 3 years
- Company has a low return on capital employed of -13.5%
- Interest coverage is weak at -8.6x - earnings barely cover interest
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.09x)
- Company's sales have been declining over the last five years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| LASA | 6.59 | 0.00 | 33.02 | 0.00 | -3.58 | 83.05 | 1.23 | -93.87 | -13.23 | -113.45 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 | 24 | 27 | 23 | 31 | 39 | 33 | 39 | 20 | 3 | 2 | -0 | 1 | |
| 27 | 23 | 26 | 27 | 29 | 39 | 33 | 36 | 21 | 7 | 3 | 2 | 4 | |
| Operating Profit | 4 | 1 | 1 | -4 | 2 | 1 | 0 | 3 | -0 | -4 | -1 | -2 | -3 |
| OPM % | 13.25% | 4.28% | 3.94% | -17.44% | 5.84% | 2.03% | 0.79% | 8.71% | -2.50% | -130.72% | -34.09% | 1630.77% | -252.16% |
| 0 | 0 | 0 | -9 | 0 | 2 | 9 | -22 | -20 | 0 | 0 | -0 | 1 | |
| Interest | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 2 | 2 | 2 | 1 | 2 |
| Profit before Tax | 1 | -2 | -2 | -16 | -2 | -1 | 6 | -22 | -23 | -6 | -2 | -4 | -3 |
| Tax % | 580.58% | 99.05% | 29.61% | 4.20% | -46.77% | -146.56% | 7.11% | 35.40% | 6.30% | -10.04% | -5.81% | -4.77% | -3.02% |
| Net Profit | -5 | -0 | -1 | -15 | -3 | -3 | 5 | -14 | -21 | -6 | -3 | -4 | -4 |
| -0.99 | 0.00 | -0.29 | -3.05 | -0.55 | -0.64 | 1.10 | -2.85 | -4.22 | -1.25 | -0.51 | -0.83 | -0.71 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 199 | 244 | 170 | 167 | 202 | 137 | 130 | 104 | 6 | |
| 0 | 153 | 202 | 159 | 137 | 155 | 121 | 136 | 102 | 16 | |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -7 | 2 | -10 |
| OPM % | — | 22.91% | 16.94% | 6.52% | 17.92% | 23.33% | 11.68% | -5.09% | 2.13% | -156.74% |
| 0 | -24 | 3 | 1 | 0 | 0 | -8 | -18 | -9 | 0 | |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 0 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 6 |
| Profit before Tax | 0 | 2 | 15 | -16 | 5 | 29 | -6 | -42 | -19 | -16 |
| Tax % | — | -10.25% | 18.99% | 25.29% | 23.39% | 22.76% | 13.16% | 8.62% | -13.70% | -6.47% |
| Net Profit | 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -17 |
| EPS | 0.00 | 472.48 | 5.43 | -5.27 | 1.26 | 5.60 | -1.06 | -7.71 | -4.34 | — |
| Dividend Payout % | — | 0.00% | 0.00% | 0.00% | 0.00% | 4.46% | -23.49% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- -9%
- 3 Years:
- -20%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- -38%
- 3 Years:
- -39%
- 1 Year:
- -49%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- -7%
- 3 Years:
- -17%
- Last Year:
- -20%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0 | 0 | 23 | 23 | 41 | 41 | 50 | 50 | 50 |
| 0 | 55 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | |
| 0 | 104 | 90 | 69 | 34 | 0 | 0 | 0 | 0 | |
| Trade Payables | 0 | 25 | 48 | 60 | 34 | 13 | 17 | 9 | 14 |
| 0 | 44 | 31 | 22 | 19 | 36 | 34 | 36 | 40 | |
| Total Liabilities | 0 | 228 | 287 | 255 | 229 | 208 | 209 | 164 | 151 |
| 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | |
| Capital Work in Progress | 0 | 29 | 7 | 7 | 0 | 0 | 5 | 5 | 3 |
| 0 | 33 | 42 | 32 | 26 | 17 | 11 | 14 | 19 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | |
| Cash & Bank | 0 | 1 | 3 | 3 | 6 | 4 | 17 | 2 | 1 |
| 0 | 45 | 65 | 53 | 44 | 43 | 38 | 24 | 14 | |
| Total Assets | 0 | 228 | 287 | 255 | 229 | 208 | 209 | 164 | 151 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| -0 | -3 | 43 | 44 | 14 | 41 | 12 | -17 | 2 | |
| Cash from Investing | 0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | -0 |
| Cash from Financing | 0 | 0 | 4 | -33 | -10 | -36 | -0 | -4 | -2 |
| 0 | -3 | 0 | -0 | 2 | 1 | 6 | -10 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-09 - Lasa Supergenerics Limited has informed the Exchange about General Updates
2026-09-09 - Lasa Supergenerics Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026.
2026-09-02 - The Exchange has sought clarification from Lasa Supergenerics Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
2026-08-26 - Appointment of Mr Janardan Savala as additonal director in capacity of Executive Director
2026-08-25 - Lasa Supergenerics Limited has informed the Exchange regarding Cessation of Mr. ganesh as Executive Director of the company w.e.f. August 25, 2026.
2026-08-25 - Lasa Supergenerics Limited has informed the Exchange about Resignation of Director/KMP/SMP
2026-08-14 - Integrated filing for Quarter ended 30 june, 2026
2026-08-14 - Lasa Supergenerics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-18 - SDD certificate for the quarter ended June 2026
News
Recent coverage and analyst commentary for LASA
Loading news…
AI Stock Analyst
Lasa Supergenerics Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account